Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026)

Revolution Medicines' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.4 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability held at $2.4 million in Q1 2026 per RVMD's latest filing, from $2.4 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $7.4 million in Q1 2022 and bottomed at $2.4 million in Q4 2024.
• The 5-year median for Non-Current Deferred Tax Liability is $3.1 million (2023), against an average of $4.3 million.
• Across the five-year window, Non-Current Deferred Tax Liability changed 0.0% in 2022 and sank 55.82% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $7.0 million in 2022, then tumbled by 55.66% to $3.1 million in 2023, then retreated by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
• Per Business Quant, the three latest RVMD Non-Current Deferred Tax Liability figures stand at $2.4 million (Q1 2026), $2.4 million (Q4 2025), and $2.4 million (Q3 2025).